Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Report 1:b:ii Benefit - Risk Wave 1 Case Study Report: Ketek® - Number needed to harm - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-07-16 01:09:14 Statistics Ethics Risk management Epidemiology Operations research Telithromycin Decision making Risk Number needed to harm Decision theory Medical statistics Management		Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Report 1:b:ii Benefit - Risk Wave 1 Case Study Report: Ketek® Add to Reading List Source URL: protectbenefitrisk.eu Download Document from Source Website File Size: 4,38 MB Share Document on Facebook

	Aquis Exchange Monthly Statistics Feb-2017 € 13,938,544,778 1,068,768,383 Value Traded DocID: 1xVY0 - View Document
	Aquis Exchange Monthly Statistics Feb-2016 € 5,995,146,,183,444 Nestle SA DocID: 1xVWK - View Document
	Aquis Exchange Monthly Statistics Feb-2018 € 17,012,038,916 1,321,056,240 Nestle SA DocID: 1xVRB - View Document
	Aquis Exchange Monthly Statistics May-2016 € 6,758,607,,245,455 Novartis AG DocID: 1xVO3 - View Document
	Aquis Exchange Monthly Statistics Month: Value traded (EUR): Volume (no. of shares): Jun-2017 DocID: 1xVNh - View Document